ライフサイエンスコーパス: effusion

1 depression, and new or worsening pericardial effusion).

2 rial mass and moderate to severe pericardial effusion.

3 lectrocardiographic changes, and pericardial effusion.

4 btained and indicated increasing pericardial effusion.

5 al space as seen in other forms of choroidal effusion.

6 tive AF or postoperative pericardial/pleural effusion.

7 MPP children or in MPP children with pleural effusion.

8 postoperative AF and pericardial or pleural effusion.

9 performed to identify the cause of a pleural effusion.

10 ciated with lower incidence of parapneumonic effusion.

11 ut steam pop, impedance rise, or pericardial effusion.

12 se of hypotension from a serious pericardial effusion.

13 ion and dysfunction, and a large pericardial effusion.

14 6 bpm, p<0.01) than those with lower pleural effusion.

15 pia with ciliary body edema and supraciliary effusion.

16 as well as ascites and a left-sided pleural effusion.

17 eniscal morphology/extrusion, synovitis, and effusion.

18 aracters, such as refractoriness and pleural effusion.

19 lease of inflammatory cytokines, and pleural effusion.

20 to have periaortic hematoma and pericardial effusion.

21 and interatrial septum and mild pericardial effusion.

22 ory device position and excluded pericardial effusion.

23 lobe mass along with a moderate-size pleural effusion.

24 d pulmonary edema with a small right pleural effusion.

25 y diagnose tuberculous and malignant pleural effusion.

26 vidence for late pericardial inflammation or effusion.

27 wed an enlarged heart with bilateral pleural effusion.

28 efinitive treatment of recurrent symptomatic effusion.

29 pleural effusions from transudative pleural effusions.

30 nts limits or delays clearance of middle ear effusions.

31 Cs are elevated in MPEs compared with benign effusions.

32 T2-weighted sequences revealed small pleural effusions.

33 were more likely to have significant pleural effusions.

34 ma effusions from other malignant and benign effusions.

35 ptide-encoding gene in chinchilla middle ear effusions.

36 duces complication rates, particularly uveal effusions.

37 edema and fibrosis and frequent pericardial effusions.

38 effusions, chylothoraces and/or pericardial effusions.

39 spontaneously resolving) included choroidal effusion (1), vitreous hemorrhage (3), Descemet detachme

40 e device embolization (1.9%) and pericardial effusion (1.9%), with no cases of periprocedural stroke.

41 Lung nodules (75%, kappa = 0.71) and effusions (100%, kappa = 0.89) were also well visualized

42 2% vs 40.5%, P < 0.001), symptomatic pleural effusion (11.6% vs 26.4%, P = 0.003), pleural effusion r

43 intrathoracic lymphadenopathy (16%), pleural effusion (12%), reticular infiltration (4%), and pericar

44 rvival compared with those with nonmalignant effusions (16.2% vs. 49.0%, respectively; log-rank test

45 omes (ACS) (1C), the presence of pericardial effusion (1C), cardiac tamponade (1B), valvular dysfunct

46 reticular infiltration (4%), and pericardial effusion (4%).

47 ltoid bursa/long head of bicep tendon sheath effusion (44.4%), and long head of bicep tendon sheath e

48 esent in 9); edema (9); respiratory (6); and effusions (5).

49 23%), mass-like consolidation (17%), pleural effusion (8.6%), and honey combing (5.7%).

50 The most frequent complications were uveal effusion (9.3%) and cystoid macular edema (CME) (7.0%).

51 ography domains (adequate views, pericardial effusion, acute cor pulmonale, left ventricular ejection

52 atic cardiac events (symptomatic pericardial effusion, acute coronary syndrome, pericarditis, signifi

53 ndinosis, subacromial-subdeltoid bursitis or effusion and adhesive capsulitis.

54 ures was strong (eg, alpha = .78 for pleural effusion and ascites) but was lower for others (eg, alph

55 use of ultrasonography for ruling-in pleural effusion and assisting its drainage, ascites drainage, r

56 cally as interstitial pneumonia with pleural effusion and clinically as hypoxemic respiratory insuffi

57 CAP with pleural effusion and documented pneumococcal CAP were diagnosed

58 inib compared with imatinib, whereas pleural effusion and grade 3/4 thrombocytopenia were more freque

59 When pleural effusion and intra-abdominal hypertension were simultane

60 Among patients with malignant pleural effusion and no previous pleurodesis, there was no signi

61 d to alectinib: acute renal failure; pleural effusion and pericardial effusion; and brain metastasis.

62 pigastric pain was found to have pericardial effusion and pneumopericardium on computed imaging.

63 ictors of patellofemoral cartilage loss were effusion and prevalent cartilage damage in the same subr

64 ouse models of malignant lung cancer pleural effusion and spontaneous colon cancer metastasis.

65 One patient had transient choroidal effusion and undercorrection.

66 of leukocytes and malignant cells in pleural effusions and accurately predict disease state in patien

67 o patients, including one with large pleural effusions and another with ventricular tachycardia, were

68 itoneal spread, presence and size of pleural effusions and ascites, lymphadenopathy, and distant meta

69 improve the drainage of complicated pleural effusions and empyemas and it is the most effective drug

70 Pericardial effusions and myocardial fibrosis were 3 and 4x more com

71 more frequently complicated with pericardial effusions and periaortic hematoma.

72 tly post antibiotic treatment in the pleural effusions and pleural macrophages up-regulated markers c

73 dothelial necrosis surrounded by hemorrhagic effusions and pulmonary edema.

74 tumor, pleural metastases, malignant pleural effusion, and ascites obtained during disease progressio

75 thickening of the gallbladder wall, pleural effusion, and ascites.

76 ignment, tibiofemoral cartilage damage, knee effusion, and body mass index with meniscal extrusion we

77 est a strong impact of PCV13 on CAP, pleural effusion, and documented pneumococcal pneumonia, particu

78 ac, peritoneal implants, ipsilateral pleural effusion, and intratumoral hemorrhage.

79 Reported events included seizure, pleural effusion, and lymphocytopenia.

80 ductus arteriosus, cardiomegaly, pericardial effusion, and lymphoedema.

81 eath, stroke, systemic embolism, pericardial effusion, and major bleeding were 5.8%, 1.9%, 0%, 1.9%,

82 sions, meniscal damage/extrusion, synovitis, effusion, and prevalent cartilage damage in the same sub

83 4 patients with mesothelioma, 39 with benign effusions, and 54 with malignant effusions not due to me

84 toms are bilateral lower limb edema, serosal effusions, and vitamin D malabsorption resulting in oste

85 al failure; pleural effusion and pericardial effusion; and brain metastasis.

86 Effusions are a key determinant of postoperative length-

87 erious complications associated with chylous effusions are well known.

88 creased gall bladder wall thickness, pleural effusion, ascites, hepatomegaly, and splenomegaly are hi

89 athologic entity that usually presents as an effusion-associated fibrous capsule surrounding an impla

90 be instrumental to the treatment of pleural effusion-associated lung restriction and cyclical tidal

91 MGAS5005 induced vascular effusion at infection sites at early hours after GAS ino

92 1 patient developed pericardial and pleural effusion attributed to pericardial instrumentation.

93 inked with Kaposi's sarcoma (KS) and primary effusion B-cell lymphoma (PEL), respectively.

94 only help in diagnosing pneumothoracies and effusions but also look at lung recruitment and diaphrag

95 There were no pericardial effusions, but serious procedure/device-related events o

96 % to 29.7% (P < .001), the number of pleural effusion cases decreased by 53% (167 to 79; P < .001) an

97 The absolute risk of hypotony, choroidal effusion, cataract, and flat or shallow anterior chamber

98 Malignant pleural effusion causes disabling dyspnea in patients with a sho

99 ding bleb leak, hypotony, hyphema, choroidal effusion, choroidal hemorrhage, blebitis, and endophthal

100 l and/or pulmonary lymphangiectasia, pleural effusions, chylothoraces and/or pericardial effusions.

101 Chylous pleural effusion (chylothorax) frequently accompanies lymphatic

102 17.6%) or postoperative pericardial/pleural effusion (colchicine, 103 patients [57.2%]; placebo, 106

103 Moreover, chronic OM with effusion (COME) is the leading cause of conductive heari

104 Chronic otitis media with effusion (COME) is the most common cause of hearing loss

105 ated whether fibulin-3 in plasma and pleural effusions could meet sensitivity and specificity criteri

106 Among patients with malignant pleural effusion, daily drainage of pleural fluid via an indwell

107 MCs were required for effusion development, as MPEs did not form in mice lacki

108 gher morbidity of tachypnea/dyspnea, pleural effusion, diarrhea, hepatosplenomegaly, consciousness al

109 Middle ear effusion disappeared 2.0 weeks (13.7 days) earlier (P =

110 NK cells isolated from inflammatory pleural effusions display a potent regulatory activity.

111 ve overall survival in patients with pleural effusion due to malignant pleural mesothelioma, and talc

112 ve a history of asbestos exposure or pleural effusion due to various causes.

113 eeks plus tremelimumab 1 mg/kg), pericardial effusion (durvalumab 20 mg/kg every 4 weeks plus tremeli

114 Effusion fibulin-3 levels were significantly higher in p

115 In conjunction with effusion fibulin-3 levels, plasma fibulin-3 levels can f

116 MPE formation and suggest that MC-dependent effusion formation is therapeutically addressable.

117 evels can further differentiate mesothelioma effusions from other malignant and benign effusions.

118 o detected CXCL12-gamma in malignant pleural effusions from patients with breast cancer.

119 asopharynx of healthy children or middle ear effusions from patients with otitis media, revealed a st

120 an help in differentiating exudative pleural effusions from transudative pleural effusions.

121 e to mesothelioma, and 43 healthy controls), effusions (from 74 patients with mesothelioma, 39 with b

122 vs. 80+/-87 mL, p<0.0001, for higher pleural effusion group vs. lower pleural effusion group) was gre

123 vs. 23+/-29 mL, p<0.0001 for higher pleural effusion group vs. lower pleural effusion group, respect

124 her pleural effusion group vs. lower pleural effusion group) was greater than the estimated lung comp

125 her pleural effusion group vs. lower pleural effusion group, respectively).

126 s were divided into higher and lower pleural effusion groups according to the median value (287 mL).

127 Lung cancer patients with proven malignant effusions had a significantly shorter median 1-year surv

128 RATIONALE: Patients with malignant pleural effusions have significant dyspnea and shortened life ex

129 4; P<0.001), and the presence of pericardial effusion (HR, 1.38; 95% confidence interval, 1.023-1.862

130 ith pulmonary infiltrates, pleuropericardial effusion, hypotension, and renal failure.

131 9.5%) patients including symptomatic pleural effusion in 366 (30.1%) patients, respiratory insufficie

132 Pleural effusion in acute lung injury or acute respiratory distr

133 sophagopericardial fistulas with pericardial effusion in all patients, while contrast leakage and air

134 p = 0.0161) were associated with pericardial effusion in females relative to healthy females.

135 To assess the effects of pleural effusion in patients with acute lung injury on lung volu

136 use of ICS on the incidence of parapneumonic effusion in patients with different baseline respiratory

137 defined as abnormal central lymphatic flow, effusions in more than 1 compartment, and dermal backflo

138 Unilateral pleural effusion instillation (13 mL/kg), intra-abdominal hypert

139 cifically disrupts the BTB and enhances drug effusion into brain tumors.

140 TB, but not the BBB, thereby increasing drug effusion into established tumors and enhancing the chemo

141 tension (15 mm Hg), and simultaneous pleural effusion/intra abdominal hypertension.

142 Pleural effusion is a frequent finding in patients with acute re

143 ied by hypotension and cyanosis, pericardial effusion, low voltage on the electrocardiogram, marked e

144 nocompromised individuals, including primary effusion lymphoma (PEL) and Kaposi's sarcoma (KS).

145 orders of these cells manifesting as primary effusion lymphoma (PEL) and multicentric Castleman disea

146 other lymphoproliferative disorders, primary effusion lymphoma (PEL) and multicentric Castleman's dis

147 Kaposi's sarcoma (KS) and primary effusion lymphoma (PEL) are two well-known inflammation

148 otein, and in KSHV latently infected primary effusion lymphoma (PEL) BCBL-1 and BC-3 cells.

149 associated nuclear antigen (LANA) in primary effusion lymphoma (PEL) cell lines and also increases th

150 ly impacting HHV-8 latently infected primary effusion lymphoma (PEL) cell viability and reactivated v

151 Primary effusion lymphoma (PEL) cells are predominantly infected

152 d knockdown of KAP1 in KSHV-infected primary effusion lymphoma (PEL) cells disrupted viral episome st

153 In primary effusion lymphoma (PEL) cells infected with latent Kapos

154 iASPP to KSHV-infected-cell growth, primary effusion lymphoma (PEL) cells were treated with an iASPP

155 In primary effusion lymphoma (PEL) cells, vIL-6 is expressed latent

156 stable episome in latently infected pleural effusion lymphoma (PEL) cells.

157 d Epstein-Barr virus-coinfected JSC1 primary effusion lymphoma (PEL) cells.

158 viral cytokine in latently infected primary effusion lymphoma (PEL) cells.

159 in KS lesions and in KSHV-associated primary effusion lymphoma (PEL) cells.

160 n, and proliferation of BCR-negative primary effusion lymphoma (PEL) cells.

161 nesis and the survival and growth of primary effusion lymphoma (PEL) cells.

162 Primary effusion lymphoma (PEL) is a highly aggressive B-cell ma

163 Primary effusion lymphoma (PEL) is a largely incurable malignanc

164 Primary effusion lymphoma (PEL) is a lymphogenic disorder associ

165 Primary effusion lymphoma (PEL) is a rare B-cell neoplasm in whi

166 Primary effusion lymphoma (PEL) is a rare form of aggressive B c

167 -cell non-Hodgkin lymphomas (B-NHL), primary effusion lymphoma (PEL) is a unique subset that is linke

168 Primary effusion lymphoma (PEL) is an aggressive form of non-Hod

169 Primary effusion lymphoma (PEL) is an aggressive subtype of non-

170 Primary effusion lymphoma (PEL) is an aggressive type of non-Hod

171 Primary effusion lymphoma (PEL) is an AIDS-defining cancer.

172 the vIRF3-expressing KSHV-associated primary effusion lymphoma (PEL) lines are generally resistant to

173 or the survival and proliferation of primary effusion lymphoma (PEL), an aggressive malignancy associ

174 KSHV is linked to primary effusion lymphoma (PEL), and 90% of PELs also contain EB

175 is the cause of Kaposi sarcoma (KS), primary effusion lymphoma (PEL), and a form of Castleman disease

176 ative agent for Kaposi sarcoma (KS), primary effusion lymphoma (PEL), and a subset of multicentric Ca

177 on of KSHV from Kaposi sarcoma (KS), primary effusion lymphoma (PEL), and multicentric Castleman dise

178 o virus-associated Kaposi's sarcoma, primary effusion lymphoma (PEL), and multicentric Castleman's di

179 evelopment of Kaposi's sarcoma (KS), primary effusion lymphoma (PEL), and multicentric Castleman's di

180 ive diseases: Kaposi's sarcoma (KS), primary effusion lymphoma (PEL), and multicentric Castleman's di

181 is associated with Kaposi's sarcoma, primary effusion lymphoma (PEL), and multicentric Castleman's di

182 oplastic diseases: Kaposi's sarcoma, primary effusion lymphoma (PEL), and multicentric Castleman's di

183 o HHV-8-associated Kaposi's sarcoma, primary effusion lymphoma (PEL), and multicentric Castleman's di

184 sociated with Kaposi's sarcoma (KS), primary effusion lymphoma (PEL), and multicentric Castleman's di

185 rus (KSHV) is the etiologic agent of primary effusion lymphoma (PEL), multicentric Castleman's diseas

186 including Kaposi's sarcoma (KS) and primary effusion lymphoma (PEL).

187 iated with Kaposi's sarcoma (KS) and primary effusion lymphoma (PEL).

188 ntric Castleman's disease (MCD), and primary effusion lymphoma (PEL).

189 cies, including Kaposi's sarcoma and primary effusion lymphoma (PEL).

190 AIDS-related Kaposi sarcoma (KS) and primary effusion lymphoma (PEL).

191 i sarcoma, or the B-cell malignancy, primary effusion lymphoma (PEL).

192 including Kaposi's sarcoma (KS) and primary effusion lymphoma (PEL).

193 including Kaposi's sarcoma (KS) and primary effusion lymphoma (PEL).

194 with several malignancies, including primary effusion lymphoma (PEL).

195 g in HHV-8 productive replication in primary effusion lymphoma and endothelial cells.

196 svirus that has been associated with primary effusion lymphoma and multicentric Castleman's disease,

197 -cell genomes of a latently infected pleural effusion lymphoma cell line BCBL1.

198 ression in a subset of KSHV-infected primary effusion lymphoma cell lines as a consequence of altered

199 re microRNA expression in a panel of primary effusion lymphoma cell lines by real-time RT-PCR recapit

200 and in vivo, and Kaposi sarcoma and primary effusion lymphoma cells demonstrate high levels of D6 ex

201 ssion on EC and MHC-II expression on primary effusion lymphoma cells, but its effects on EC MHC-II ex

202 ction and KSHV lytic reactivation in primary effusion lymphoma cells.

203 we tested a BCL2 family inhibitor in primary effusion lymphoma cells.

204 d the teHsp90 interactome in KSHV(+) primary effusion lymphoma cells.

205 lytic reactivation in KSHV-positive primary effusion lymphoma cells.

206 l as a rare form of B cell lymphoma (primary effusion lymphoma) primarily observed in HIV-infected in

207 the development of Kaposi's sarcoma, primary effusion lymphoma, and multicentric Castleman's disease

208 the development of Kaposi's sarcoma, primary effusion lymphoma, and multicentric Castleman's disease.

209 gic agent underlying Kaposi sarcoma, primary effusion lymphoma, and multicentric Castleman's disease.

210 e etiologic agent of Kaposi sarcoma, primary effusion lymphoma, and plasma cell-type multicentric Cas

211 ogical agent of Kaposi's sarcoma and primary effusion lymphoma, has developed a unique mechanism to d

212 multicentric Castleman's disease and primary effusion lymphoma.

213 s (KSHV) causes Kaposi's sarcoma and primary effusion lymphoma.

214 Primary effusion lymphomas (PEL) are associated with human herpe

215 merous human malignancies, including primary effusion lymphomas (PELs).

216 i's sarcoma, Castleman's disease and primary effusion lymphomas in transplant recipients.

217 KSHV causes primary effusion lymphomas, multicentric Castleman's disease, an

218 romatic compounds are measured using Knudsen Effusion Mass Spectrometry (KEMS) over a range of temper

219 Malignant pericardial effusion may require emergency pericardiocentesis if car

220 atrial fibrillation (AF), and postoperative effusions may be responsible for increased morbidity and

221 bial treatment on the duration of middle ear effusion (MEE) and concomitant hearing impairment is not

222 MPE formation in a human cancer cell-induced effusion model.

223 Malignant pleural effusion (MPE) is the lethal consequence of various huma

224 Malignant pleural effusion (MPE) poses a significant clinical problem.

225 al effusion (TPE, n = 50), malignant pleural effusion (MPE, n = 41), other cases including pneumonia

226 ed MCs in human and murine malignant pleural effusions (MPEs) and evaluated the fate and function of

227 s post-operatively (n = 2), late pericardial effusion (n = 1), unexplained sudden death (n = 2), and

228 ed patients with pneumonia (n = 28), pleural effusion (n = 13), pleural empyema (n = 4), lung abscess

229 (n = 9), pupillary block (n = 1), choroidal effusion (n = 2), CME (n = 4), and redislocation (n = 1)

230 nts at a median of 26 months to first event (effusion [n = 7], myocardial infarction [n = 5], unstabl

231 included age, ejection fraction, pericardial effusion, N-terminal pro-B-type natriuretic peptide, and

232 For treatment of malignant pleural effusion, nonsteroidal anti-inflammatory drugs (NSAIDs)

233 n the New York cohort) than in patients with effusions not due to mesothelioma (212+/-25 and 151+/-23

234 with benign effusions, and 54 with malignant effusions not due to mesothelioma), or both.

235 sed persons without cancer, 93 patients with effusions not due to mesothelioma, and 43 healthy contro

236 Significant pericardial effusion occurred in 16 patients (10.4%).

237 ated with a lower incidence of parapneumonic effusion (odds ratio, 0.40; 95% confidence interval, 0.2

238 terval, 1.4-6.2; P<0.001), and a pericardial effusion (odds ratio, 2.5; 95% confidence interval, 1.1-

239 Otitis media with effusion (OME) is the most common cause of hearing loss

240 Chronic Otitis media with effusion (OME) often leads to conductive hearing loss an

241 values in the area of the greatest amount of effusion on each slice of the three slices used.

242 periaortic hematoma, and hemorrhagic pleural effusion on imaging identify patients with complicated a

243 rit <30% (OR, 2.0; 95% CI, 1.3-3.2), pleural effusion on presenting chest x-ray (OR, 1.6; 95% CI, 1.1

244 ndred and twenty eight patients with pleural effusions on thoracic CT who underwent thoracentesisis w

245 44.4%), and long head of bicep tendon sheath effusion only (40%).

246 d no evidence of pericardial adhesion and/or effusion or adverse effect on cardiac function.

247 Patients with NSCLC (stage IIIB with pleural effusion or stage IV according to American Joint Committ

248 Patients with stage IIIB (with pleural effusion or supraclavicular nodes) to IV NSCLC and perfo

249 C [>100.4 degrees F], subacute course, large effusion or tamponade, and failure of nonsteroidal anti-

250 l maceration (OR, 1.84; 95% CI: 1.13, 2.99), effusion (OR, 4.75; 95% CI: 2.55, 8.85), or synovitis (O

251 , who also exhibit polycythemia, pericardial effusion, or goiter should be evaluated for cobalt expos

252 my group, eyes developed postoperative uveal effusions (P = .04).

253 Pericardial effusion (PE) is common in cancer patients, but the opti

254 ents had bleeding complications (pericardial effusion, pericardial hematoma, hemoperitoneum, and peri

255 studied were the occurrence of PPCs, pleural effusion, pneumonia, and pulmonary embolism.

256 he c-KIT inhibitor imatinib mesylate limited effusion precipitation by mouse and human adenocarcinoma

257 l damage, meniscal extrusion, synovitis, and effusion prior to reported knee replacement.

258 were 4 independent risk factors for pleural effusion: prolonged surgery (OR = 1), surgery on the rig

259 l performance index, presence of pericardial effusion, pulmonary vascular resistance, cardiac index,

260 spite high lava viscosities and low inferred effusion rates, can result in remarkably, laterally exte

261 irmed or suspected mesothelioma with pleural effusion, recruited from 12 hospitals in the UK.

262 Procedure-related complications, effusion recurrence rate, and overall survival were anal

263 However, postoperative effusions remain a significant challenge.

264 ffusion (11.6% vs 26.4%, P = 0.003), pleural effusion requiring drainage (1.7% vs 9.9%, P = 0.006), a

265 P<0.0001) associated with pneumonia, pleural effusions requiring drainage, and maximum postoperative

266 Pericardial effusions requiring surgical repair decreased from 1.6%

267 Evaluation of human effusions revealed that MCs are elevated in MPEs compare

268 igns (ie, halo sign, hypodense sign, pleural effusion, reversed halo sign) is unknown.

269 HH is a transudative pleural effusion seen in 5%-10% of cirrhosis patients, in the ab

270 dyspnoea (six [2%] vs one [1%]), and pleural effusion (six [2%] vs none).

271 were thrombocytopenia (eight [11%]), pleural effusion (six [8%]), and increased lipase (five [7%]).

272 a conductive deafness arising from a chronic effusion starting at around 3 weeks of age.

273 of emp2 in zebrafish resulted in pericardial effusion, supporting the pathogenic role of mutated EMP2

274 rregularities include: synovial pathologies, effusion, tendon, cartilage and bone lesions, tendon and

275 ssion from a non-infected, pneumonia-related effusion to a confirmed pleural infection have been well

276 ly in the absence of preexisting pericardial effusion to provide a novel route for cardiac cellular r

277 lled 91 cases, including tuberculous pleural effusion (TPE, n = 50), malignant pleural effusion (MPE,

278 Pleural effusion volume was determined on each CT scan section;

279 g medium lobe atelectasis; bilateral pleural effusion was also present.

280 Incidence of parapneumonic effusion was lower in patients with ICS use compared wit

281 1 hemodynamically insignificant pericardial effusion was observed at follow-up.

282 nal residual capacity by 368 mL when pleural effusion was present and by 184 mL when intra-abdominal

283 ntified in either treatment arm, and pleural effusion was the only drug-related, nonhematologic adver

284 ecurrent, nonresponsive, and chronic OM with effusion) was greater than that on simple, acute OM in p

285 The best-performing MRI feature (synovitis/effusion) was not significantly more informative than K/

286 Patients with higher pleural effusion were older (62+/-16 yr vs. 54+/-17 yr, p<0.01)

287 First occurrences of pleural effusion were reported with dasatinib, with the highest

288 Pleural effusions were classified as exudates or transudates acc

289 Orthotopic tumors and pleural effusions were clearly visualized at MR imaging 3 weeks

290 lysis, and levels of fibulin-3 in plasma and effusions were measured with an enzyme-linked immunosorb

291 The incidence of pleural effusions were not significantly different between both

292 Thirty three (26%) of the 128 pleural effusions were transudates and 95 (74%) were exudates.

293 enia (40 [5%] vs 23 [3%]); grade 3-4 pleural effusions were uncommon (ten [1%] vs three [<1%]).

294 logic findings (multiple nodules and pleural effusion) were less frequent, but appeared later in the

295 as hyperacusis and chronic otitis media with effusion, which is prevalent in young children with lang

296 rved LVEF in 2, and an important pericardial effusion with tamponade in another.

297 hyperintense (infection), and a homogeneous effusion with the signal intensity of fluid (nonspecific

298 gnificantly higher rate of large pericardial effusions with LBN compared with MPN (8.1% versus 0.9%;

299 phy (CT) findings for characterizing pleural effusions with the use of attenuation values.

300 ictors of patellofemoral cartilage loss were effusion, with an adjusted odds ratio (OR) of 3.5 (95% c